ES2187568T3 - Vacuna viva para el tratamiento de enfermedades tumorales. - Google Patents

Vacuna viva para el tratamiento de enfermedades tumorales.

Info

Publication number
ES2187568T3
ES2187568T3 ES95929003T ES95929003T ES2187568T3 ES 2187568 T3 ES2187568 T3 ES 2187568T3 ES 95929003 T ES95929003 T ES 95929003T ES 95929003 T ES95929003 T ES 95929003T ES 2187568 T3 ES2187568 T3 ES 2187568T3
Authority
ES
Spain
Prior art keywords
vaccine
cells
gene
against tumor
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95929003T
Other languages
English (en)
Inventor
Thomas Blankenstein
Sophie Cayeux-Pezzutto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Application granted granted Critical
Publication of ES2187568T3 publication Critical patent/ES2187568T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001136Cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION TRATA DE LA OBTENCION Y UTILIZACION DE UNA VACUNA VIVA CONTRA CELULAS TUMORALES, QUE CONTIENE TRES GENES ADICIONALES OBTENIDOS POR INGENIERIA GENETICA: A) UN GEN QUE CODIFICA UNA PROTEINA DE LA SUPERFICIE CELULAR CON ACTIVIDAD INMUNOESTIMULANTE; B) UN GEN DE CITOQUINA, Y C) UN GEN DE TIMIDINA-QUINASA. LOS CAMPOS DE APLLICACION SON LA MEDICINA Y LA INGENIERIA GENETICA. LA INVENCION PROPONE UNA VACUNA CONTRA CELULAS TUMORALES, QUE TIENE SU EFECTIVIDAD PORQUE SE INDUCE UNA RESPUESTA ANTITUMORAL DE MANERA SINERGICA POR LA MULTIPLE TRANSFERENCIA DE GENES, QUE CODIFICAN LA ACTIVIDAD INMUNOESTIMULANTE. ESTO NOS LLEVA A UNA SEGURA REPULSION DE LAS CELULAS DE LA VACUNA Y NOS PERMITE INYECTAR COMO VACUNA CELULAS CAPACES DE MULTIPLICARSE. COMO MARCADORES ADICIONALES DE SEGURIDAD CONTIENEN LAS CELULAS DE LA VACUNA EL GEN DE LA TIMIDINA-QUINASA, QUE PERMITE LA MUERTE SELECTIVA DE LAS CELULAS DE LA VACUNA IN VIVO. LA EXPRESION DE LOS GENES CON ACTIVIDAD INMUNOESTIMULANTE MEJORA EL EFECTO DELA VACUNA EN COMPARACION CON VACUNAS YA CONOCIDAS CONTRA CELULAS TUMORALES, Y UNA VACUNA VIVA CONTRA CELULAS TUMORALES ES MAS EFECTIVA QUE UNA VACUNA COMPUESTA DE CELULAS CAPACES DE PROLIFERAR. LA VACUNA ES UTILIZABLE EN LA TERAPIA GENETICA EN PACIENTES CON TUMORES.
ES95929003T 1994-08-24 1995-08-18 Vacuna viva para el tratamiento de enfermedades tumorales. Expired - Lifetime ES2187568T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4431401A DE4431401A1 (de) 1994-08-24 1994-08-24 Lebendvakzine gegen Tumorerkrankungen

Publications (1)

Publication Number Publication Date
ES2187568T3 true ES2187568T3 (es) 2003-06-16

Family

ID=6527332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95929003T Expired - Lifetime ES2187568T3 (es) 1994-08-24 1995-08-18 Vacuna viva para el tratamiento de enfermedades tumorales.

Country Status (13)

Country Link
US (1) US6039941A (es)
EP (1) EP0777499B1 (es)
JP (1) JP2975117B2 (es)
KR (1) KR970705416A (es)
AT (1) ATE228016T1 (es)
AU (1) AU688101B2 (es)
BR (1) BR9508765A (es)
CA (1) CA2198234A1 (es)
DE (3) DE4431401A1 (es)
DK (1) DK0777499T3 (es)
ES (1) ES2187568T3 (es)
PT (1) PT777499E (es)
WO (1) WO1996005866A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
DE19626830A1 (de) * 1996-07-04 1998-01-08 Max Delbrueck Centrum Konditionales Immortalisationsverfahren für humane Tumorzellen zur Herstellung einer Vakzine
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
KR20000049096A (ko) 1996-10-11 2000-07-25 린다 에스. 스티븐슨 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법
AU785241B2 (en) * 2000-05-17 2006-11-23 Cancure Limited Immune potentiating compositions
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
PT2206517T (pt) * 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
JP2006096663A (ja) * 2002-10-17 2006-04-13 Sangaku Renkei Kiko Kyushu:Kk 癌遺伝子ワクチン
GB0227989D0 (en) * 2002-12-02 2003-01-08 Imp College Innovations Ltd Chimaeric molecules
AU2004275814A1 (en) * 2003-09-26 2005-04-07 University Of Miami Tumor vaccine
DK1699480T3 (da) 2003-12-30 2011-10-10 Mologen Ag Allogent terapeutisk tumormiddel
EA009325B1 (ru) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии
EP2195650B1 (en) 2007-09-12 2016-07-06 Yeda Research And Development Company Ltd. Methods of treating tumors in immune-privileged sites
RU2407789C2 (ru) * 2008-07-25 2010-12-27 Виктор Владимирович Кешелава Способ получения живой клеточной вакцины для профилактики рака молочных желез
EA011421B1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
CA2740779A1 (en) 2008-10-17 2010-04-22 University Of Miami Tumor vaccine
CN111743884A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 苄丝肼或其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91713C (fi) * 1992-04-23 1994-08-10 Axidental Oy Uusia bioaktiivisia pinnotteita ja niiden valmistus ja käyttö
ATE157261T1 (de) * 1992-05-01 1997-09-15 Us Health Warte-effekt bei tumorzerstörender therapie
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
US6039941A (en) 2000-03-21
BR9508765A (pt) 1997-11-11
DE19580890D2 (de) 1997-06-19
JPH10505339A (ja) 1998-05-26
AU688101B2 (en) 1998-03-05
AU3253195A (en) 1996-03-14
EP0777499B1 (de) 2002-11-20
MX9701384A (es) 1998-03-31
EP0777499A1 (de) 1997-06-11
DK0777499T3 (da) 2003-03-17
KR970705416A (ko) 1997-10-09
CA2198234A1 (en) 1996-02-29
DE4431401A1 (de) 1996-02-29
PT777499E (pt) 2003-03-31
WO1996005866A3 (de) 1996-04-11
DE59510466D1 (de) 2003-01-02
WO1996005866A2 (de) 1996-02-29
JP2975117B2 (ja) 1999-11-10
ATE228016T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
ES2187568T3 (es) Vacuna viva para el tratamiento de enfermedades tumorales.
Weiner et al. Genetic vaccines
Towne et al. Optogenetic control of targeted peripheral axons in freely moving animals
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
ES2185762T3 (es) Vacunas contra la peste.
JP2014101379A (ja) 遺伝子ベクターの局所施用によるワクチン接種
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
Cha et al. Plasmid IL-12 electroporation in melanoma
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
WO2004087065A8 (en) Compositions for induction of a therapeutic response
BRPI0418157A (pt) terapêutica de tumores alogênicos
DE69434244D1 (de) Verbesserte krebstherapie
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
WO2003094828A3 (en) Cancer vaccines and methods of using the same
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
Sivanathan et al. IL-17A–induced mesenchymal stem cells have promising therapeutic value for clinical translation
ES2171169T3 (es) Uso de celulas tall-104 modificadas para tratar cancer y enfermedades virales.
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
UY31184A1 (es) Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
Chiarella et al. Intramuscular DNA vaccination protocols mediated by electric fields
EP1151756A4 (en) USE OF POLYACRYLAMIDE GEL FOR PRODUCING A CAPSULE IN THE TISSUE OF A MAMMAL ORGANISM, METHOD FOR CULTURING CELLS AND METHOD FOR TREATING ONCOLOGICAL DISEASES AND DIABETES MELLITUS
Kharlamova et al. A review of past and present hair cell regeneration techniques